Related references
Note: Only part of the references are listed.Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
Yoshiya Tanaka et al.
RHEUMATOLOGY AND THERAPY (2023)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
Laura C. Coates et al.
NATURE REVIEWS RHEUMATOLOGY (2022)
Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response
Atte Valli et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2022)
Combined - whole blood and skin fibroblasts- transcriptomic analysis in Psoriatic Arthritis reveals molecular signatures of activity, resistance and early response to treatment
Alexandros Grivas et al.
FRONTIERS IN IMMUNOLOGY (2022)
Suppression of IL-23-mediated psoriasis-like inflammation by regulatory B cells
Kie Mizumaki et al.
SCIENTIFIC REPORTS (2021)
JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis
Rita A. Moura et al.
FRONTIERS IN MEDICINE (2021)
SOCS Proteins in Immunity, Inflammatory Diseases, and Immune-Related Cancer
Mohamed Luban Sobah et al.
FRONTIERS IN MEDICINE (2021)
Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)
Ana-Maria Orbai et al.
RHEUMATOLOGY (2020)
The role of JAK/STAT signaling pathway and its inhibitors in diseases
Ping Xin et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Single-cell transcriptome conservation in a comparative analysis of fresh and cryopreserved human skin tissue: pilot in localized scleroderma
Emily Mirizio et al.
ARTHRITIS RESEARCH & THERAPY (2020)
Mediation Analysis
Hopin Lee et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases (vol 16, pg 843, 2017)
Daniella M. Schwartz et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
Philip Mease et al.
LANCET (2018)
C-reactive protein upregulates the whole blood expression of CD59 - an integrative analysis
Kaido Lepik et al.
PLOS COMPUTATIONAL BIOLOGY (2017)
limma powers differential expression analyses for RNA-sequencing and microarray studies
Matthew E. Ritchie et al.
NUCLEIC ACIDS RESEARCH (2015)
mediation:RPackage for Causal Mediation Analysis
Dustin Tingley et al.
Journal of Statistical Software (2015)
Gene Expression Profiling in Peripheral Blood Cells and Synovial Membranes of Patients with Psoriatic Arthritis
Marzia Dolcino et al.
PLOS ONE (2015)
The molecular regulation of Janus kinase (JAK) activation
Jeffrey J. Babon et al.
BIOCHEMICAL JOURNAL (2014)
Immunomodulation in psoriatic arthritis: Focus on cellular and molecular pathways
Maria Sole Chimenti et al.
AUTOIMMUNITY REVIEWS (2013)
qgraph: Network Visualizations of Relationships in Psychometric Data
Sacha Epskamp et al.
JOURNAL OF STATISTICAL SOFTWARE (2012)
The Effect of the JAK Inhibitor CR-690,550 on Peripheral Immune Parameters in Stable Kidney Allograft Patients
Evelien A. F. J. van Gurp et al.
TRANSPLANTATION (2009)
Gene set enrichment analysis (GSEA) for interpreting gene expression profiles
Jing Shi et al.
CURRENT BIOINFORMATICS (2007)
Share Paper
